Prime Medicine Stock (NASDAQ: PRME) stock price, news, charts, stock research, profile.
Open | $7.050 |
Close | $7.080 |
Volume / Avg. | 610.441K / 728.582K |
Day Range | 6.870 - 7.180 |
52 Wk Range | 4.110 - 17.200 |
Market Cap | $863.022M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 70 |
Short Interest | 19.04% |
Days to Cover | 12.36 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Prime Medicine (NASDAQ: PRME) through any online brokerage.
Other companies in Prime Medicine’s space includes: Immunome (NASDAQ:IMNM), ARS Pharmaceuticals (NASDAQ:SPRY), 89bio (NASDAQ:ETNB), Humacyte (NASDAQ:HUMA) and Zentalis Pharma (NASDAQ:ZNTL).
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by Citigroup on Thursday, May 16, 2024. The analyst firm set a price target for 10.00 expecting PRME to rise to within 12 months (a possible 39.08% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Prime Medicine (NASDAQ: PRME) is $7.19 last updated May 17, 2024 at 7:50 PM EDT.
A quarterly cash dividend of $0.80 per share of Class A Common Stock. The quarterly cash dividend was payable on September 12, 2019 to stockholders of record on September 10, 2019.
Prime Medicine’s Q2 earnings are confirmed for Monday, August 5, 2024.
There is no upcoming split for Prime Medicine.
Prime Medicine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.